The FDA has approved Novo Nordisk's Victoza, or liraglutide, injection for use in patients 10 to 17 years of age with type 2 diabetes. The drug was previously approved for adults with the condition.
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.